Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1706431 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $8.64Day −2.37%Mkt cap $1.5B1Y +64.6%Off 52W high −25.9%Vol (1Y) 69.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,702 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest10.9% of sh out |
| Days to cover12.0d |
| 13F net flow (QoQ)+9.12% |
| Top-10 13F concentration57.8% |
| Next report (est.)2026-08-05 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$65.5M |
| Earnings (TTM)-$442.7M |
| Net margin−638.9% |
| ROIC−51.9% |
| Sales growth 3Y−65.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+43.3% |
| 1Y+64.6% |
| 3Y−38.6% |
| 5Y−76.3% |
| Since incept. (ann.)−6.9% |
Total return through 2026-07-29 · series begins 2019-10-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.7% |
| Ann. volatility (3Y)71.9% |
| Sharpe (1Y)1.00 |
| Sharpe (3Y)0.10 |
| Max drawdown (1Y)−23.8% |
| Max drawdown (3Y)−69.9% |
| Beta (3Y vs SPY)1.90 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 18.0M | $161M | 12.90% | +10.2% |
| ARCH Venture Management, LLC | 12.9M | $116M | 9.26% | +0.0% |
| SB INVESTMENT ADVISERS (UK) LTD | 10.9M | $98M | 7.85% | −16.5% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9.2M | $83M | 6.61% | new |
| GSK plc | 8.6M | $77M | 6.13% | +0.0% |
| STATE STREET CORP | 7.1M | $64M | 5.12% | +14.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4M | $48M | 3.86% | new |
| GOLDMAN SACHS GROUP INC | 3.3M | $29M | 2.33% | +107.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 100.4% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 16,117,209 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.85 | — | -$29,000 | −101.0% |
| 2025-12-31 | 2026-02-23 | — | — | $64.1M | +417.8% |
| 2025-09-30 | 2025-11-05 | −$1.17 | — | $240,000 | −89.9% |
| 2025-06-30 | 2025-08-06 | −$0.80 | — | $1.2M | −60.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
